Back to News
Market Impact: 0.1
SIBIONICS и PharmaSens исследуют новые горизонты для автоматической доставки инсулина на EASD 2026
Source: PR Newswire
Healthcare & BiotechProduct Launches
At the 2026 European Association for the Study of Diabetes conference, SiBionics presented its “See More, Act Earlier” program, linking continuous monitoring with future diabetes treatment. The excerpt provides no clinical results, financial figures, or market response.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Sen. Mitch McConnell closed a loophole in a hemp law he championed. Now a $28 billion THC industry that gets people high is fighting for survival
- A 'weird' IPO pull, a tainted reputation and the stalled breakout moment for AI wearables
- Apple’s John Ternus Leads Design; Touch-Screen OLED MacBook Pro Gets Lighter
- Nvidia CEO Jensen Huang has emerged as the biggest foil to AI doomerism about the existential risk to humanity
- Sports betting is increasingly the norm for Gen Z. Here’s why some financial and mental health experts are worried
- Inside Biotech: Aroa Biosurgery's Symphony improves diabetic foot ulcer healing in US clinical trial
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More
- Alternative Data Due Diligence for Institutional Investors